An integrated approach: Bisphosphonate management for the treatment of osteoporosis

American Journal of Managed Care

Volumn 13, Issue SUPPL. 11, 2007, Pages

  Owens, Gary ^a,b   Jackson, Rebecca ^c   Lewiecki, E Michael ^d,e  

^a Gary Owens Associates PA ^*  (United States)

^b Gary Owens Associates   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADMINISTRATIVE PERSONNEL; ARTHRALGIA; BONE NECROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS ULCER; FEVER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GOOD CLINICAL PRACTICE; HEADACHE; HEALTH CARE POLICY; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MANAGED CARE; MYALGIA; OSTEONECROSIS OF THE JAW; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; STOMACH ULCER; DRUG ADMINISTRATION; ECONOMICS; FALLING; FEMALE; FRACTURE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; REVIEW; UNITED STATES;

ACCIDENTAL FALLS; ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; UNITED STATES;

EID: 37849017900     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. National Osteoporosis Foundation. Fast facts on osteoporosis. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed August 14, 2007.
2. US Department of Health and Human Services. Bone Health and Osteoporosis: a Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
3. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137:1001-1005.
4. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;227:1140-1147.
5. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
6. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-650.
7. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151:2026-2032.
8. Adachi J, Magowan S, Borisov N, Lange J, Grauer A, Ohsfeldt R. Greater than 90% of managed care costs for fragility fractures are nonvertebral in nature among women. Online publication of abstract presented at The Endocrine Society's 88th Annual Meeting; May 13, 2006; Prague, Czech Republic.
9. National Osteoporosis Foundation. 8 common myths about osteoporosis. Adapted from America's bone health: the state of osteoporosis and low bone mass in our nation. Copyright NOF 2002. Available at: http://www.nof.org/ osteoporosis/diseasefacts.htm. Accessed August 23, 2007
10. IMS Health. Xponent market research data. February 2007. Available at: http://us.imshealth.com/nextgen/enh_xponent.htm. Accessed November 28, 2007
11. Healthy People 2010. Available at: http://www.healthypeople.gov/ publications. Accessed November 15, 2007
12. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorous, magnesium, vitamin D, and fluoride. Available at: http://www.10m.edu/cms/3788/4008/4253.aspx. Accessed November 28, 2007
13. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999-2006.
14. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-683.
15. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
16. Fosamax® (alendronate sodium tablets and oral solution) prescribing information. Whitehouse Station, NJ: Merck & Co; May 2007
17. Boniva® (ibandronate sodium tablets) prescribing information. Nutley, NJ: Roche Laboratories; revised August 2006.
18. Boniva® (ibandronate sodium injection) prescribing information. Nutley, NJ: Roche Laboratories; revised February 2007
19. Actonel® (risedronate sodium tablets) prescribing information. Cincinnati, OH: Procter & Gamble Pharmaceuticals; August 2006.
20. Reclast® (zoledronic acid injection) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2007
21. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 2003;1:45-52.
22. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000;373:231-241.
23. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242.
24. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006;103:7829-7834.
25. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617-627
26. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism and action of bisphosphonates. Curr Opin Pharmacol. 2006;6:307-312.
27. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Farnesyl pyrophosphatase synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999;264:108-111.
28. Rodan GA, Fleish HA. Bisphosphonates: mechanism of action. J Clin Invest. 1996;97:2692-2696.
29. Chesnut CH 3rd, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic women: effect of multiple doses on bone mass and remodeling. Am J Med. 1995;99:144-152.
30. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized control trial. Vertebral Efficacy with RisedronateTherapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
31. Bone HB, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
32. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
33. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
34. Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249.
35. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
36. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1994;333:1437-1443.
37. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-4124.
38. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004;20:433-439.
39. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15:792-798.
40. Boonen S, Laun RF, Baron IP, Watts NB. Effect of osteoporosis treatments on risk for nonvertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005;16:1291-1298.
41. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-516.
42. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-135.
43. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk for hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
44. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18:25-34.
45. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895-1896. Letter.
46. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
47. Foley KA, Foster SA, Meadows ES, Baser O, Long SR. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007;45:902-906.
48. Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023-1031.
49. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856-861.
50. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
51. Lewiecki EM. Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep. 2005;3:75-83.
52. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, Switzerland: WHO; 1994. Available at: http://whqtibdoc.who.int/trs/WHO_TRS_843.pdf. Accessed November 29, 2007
53. International Society for Clinical Densitometry (ISCD). Survey of 453 DXA facilities. 2006.
54. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-1046.
55. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J. 2006;56:178-188.
56. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int. 2007;18:9-23.
57. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int. 2002;13:765-767.